Dr Oxnard speaks with ecancer at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting about the prospects of a simple blood test for cell-free DNA (cfDNA) to detect lung cancers.

He discusses how 3 assays for targeted sequencing, whole-genome sequencing and whole-genome bisulfites sequencing can detect the circulating biomarkers of lung cancer, and considers how these could eventually be incorporated into screening and care.

For more on these results, watch his interview with ecancer, and read our news coverage here.

Slides from this presentation are available here.